Pliant Therapeutics, Inc.
700 Saginaw Drive
Suite 150
Redwood City
California
94063
United States
100 articles with Pliant Therapeutics, Inc.
-
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
3/9/2023
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter 2022 financial results.
-
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
3/8/2023
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointments of Darren Cline and Thomas McCourt to its Board of Directors.
-
Pliant Therapeutics to Participate in Upcoming Investor Events - March 1, 2023
3/1/2023
Pliant Therapeutics, Inc. today announced senior management’s participation at the following investor events in March.
-
Novartis recently announced it is returning a Phase II-ready nonalcoholic steatohepatitis asset to Pliant. The program stemmed from a 2019 collaboration.
-
Pliant Therapeutics to Participate in Upcoming Investor Events
2/7/2023
Pliant Therapeutics, Inc. today announced senior management’s participation in the following investor events in February.
-
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
2/2/2023
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for PLN-101095, an oral, small molecule, dual selective inhibitor of integrins αvβ8 and αvβ1.
-
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Jan 27, 2023
1/27/2023
Pliant Therapeutics, Inc. announced the closing of its previously announced upsized underwritten public offering of 9,583,334 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,250,000 additional shares, at a price to the public of $30.00 per share.
-
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
1/25/2023
Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced the pricing of an upsized underwritten public offering of 8,333,334 shares of its common stock at a price to the public of $30.00 per share.
-
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
1/25/2023
Pliant Therapeutics, Inc. today announced Ms. Lily Cheung as its Chief Human Resources Officer.
-
After reporting promising interim findings from the Phase IIa INTEGRIS-IPF trial, Pliant Therapeutics commenced a public stock offering of $175 million.
-
Pliant Therapeutics Announces Proposed Public Offering of Common Stock - Jan 23, 2023
1/23/2023
Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced that it has commenced an underwritten public offering of $175.0 million of its common stock.
-
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
1/22/2023
Pliant Therapeutics, Inc. announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
-
Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, will present a company update as part of the 41st Annual J.P. Morgan Healthcare Conference.
-
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
12/15/2022
Pliant Therapeutics (NASDAQ: PLRX) announced today that its lead drug candidate, bexotegrast (PLN-74809), an oral, once daily, dual-selective αvß6/αvß1 integrin inhibitor, has received Orphan Drug Designation from the European Medicines Agency (EMA) for the potential treatment of idiopathic pulmonary fibrosis (IPF).
-
Pliant Therapeutics to Participate in Upcoming November 2022 Investor Conferences
11/15/2022
Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced participation in the following November investor conferences:
-
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
11/8/2022
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2022 financial results.
-
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
10/5/2022
Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and Greg Cosgrove, M.D., FCCP, Vice President, Clinical Development, will present a corporate overview at the Pulmonary/Lung Disease Mini-Symposium, a part of RBC’s Biotech Expert Insights Series.
-
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
9/15/2022
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. Katharine Knobil to its Board of Directors, effective immediately.
-
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
9/1/2022
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced a positive safety review of the ongoing INTEGRIS-IPF Phase 2a trial of PLN-74809 at 320 mg once-daily dose in patients with idiopathic pulmonary fibrosis (IPF) from a regularly scheduled meeting of its independent Data Safety Monitoring Board (DSMB).
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences in September 2022
8/30/2022
Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and members of Pliant’s senior management will participate in the following September investor conferences.